Sign In
Buy XERS
$8.08
-0.340 (-4.04%)
At Close: Jul 31, 2026
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
08:00am, Thursday, 23'rd Jul 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
07:30am, Thursday, 23'rd Jul 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
11:40am, Wednesday, 08'th Jul 2026
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
11:00pm, Thursday, 02'nd Jul 2026
Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. Th
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10:40pm, Thursday, 02'nd Jul 2026
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:05pm, Thursday, 02'nd Jul 2026
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing
Xeris Announces Updates to Its Board of Directors
07:00am, Tuesday, 30'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
04:39pm, Thursday, 11'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient liv
Xeris Biopharma Announces Private Exchange of Convertible Notes
08:00am, Thursday, 11'th Jun 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing
Xeris Biopharma Announces Private Exchange of Convertible Notes
07:00am, Thursday, 11'th Jun 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
11:31pm, Saturday, 30'th May 2026
Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentu
Xeris Biopharma Q1 Earnings Call Highlights
04:07am, Saturday, 09'th May 2026
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
01:41pm, Thursday, 07'th May 2026
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 07'th May 2026
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street
Xeris Biopharma Reports First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
